ArticleInternational journal of molecular sciences2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- EarlyCancers · 2025Article
- Chronic Myeloid Leukemia and the T315IInternational journal of molecular sciences · 2025Review
- Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission.JCO clinical cancer informatics · 2025Article
- The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.Haematologica · 2024Article
- Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Glioblastoma,Frontiers in neurology · 2022Review
- Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.Journal of clinical medicine · 2021Article
- A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic.Diagnostics (Basel, Switzerland) · 2021Article
- Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors.International journal of molecular sciences · 2021Article
- Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of AtypicalFrontiers in pharmacology · 2021Article
- Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.Scientific reports · 2020Article
- Article
- Optimal Response in a Patient With CML ExpressingIn vivo (Athens, Greece)Article
- Targeting BCL-2 as a Therapeutic Strategy for PrimaryIn vivo (Athens, Greece)Article
- Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 1 country.
Stefania StellaDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. stefania.stel@gmail.com.
Valentina ZammitDivision of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. valentina.zammit@tiscali.it.
Silvia Rita VitaleDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. silviarita.vitale@gmail.com.
Maria Stella PennisiDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. perny76@gmail.com.
Michele MassiminoDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. michedot@yahoo.it.
Elena TirròDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. ele_tir@yahoo.it.ORCID 0000-0001-8012-5134
Stefano ForteMediterranean Institute of Oncology, 95029 Viagrande, Italy. stefano.forte@grupposamed.com.ORCID 0000-0001-5746-7451
Antonio SpitaleriDivision of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. dottspitaleriantonio@gmail.com.
Agostino AntolinoDepartment of Transfusional Medicine, Maria Paternò-Arezzo Hospital, 97100 Ragusa, Italy. agostino.antolino@asp.rg.it.
Sergio SiracusaDivision of Hematology, A.O.U. Policlinico "P. Giaccone", University of Palermo, 90127 Palermo, Italy. sergio.siragusa@unipa.it.
Vincenzo AccursoDivision of Hematology, A.O.U. Policlinico "P. Giaccone", University of Palermo, 90127 Palermo, Italy. casteldaccia@tiscali.it.
Donato ManninaDivision of Hematology, Papardo Hospital, 98158 Messina, Italy. donamanni@gmail.com.
Stefana ImperaDivision of Oncology and Hematology, ARNAS Garibaldi-Nesima, 95122 Catania, Italy. st.impera@alice.it.
Caterina MusolinoDivision of Hematology, University of Messina, 98125 Messina, Italy. cmusolino@unime.it.
Sabina RussoDivision of Hematology, University of Messina, 98125 Messina, Italy. sabinarusso@tiscali.it.
Alessandra MalatoDivision of Hematology and Bone Marrow Transplant, Villa Sofia-Cervello Hospital, 90146 Palermo, Italy. alessandramalato@hotmail.com.
Giuseppe MineoDivision of Hematology, San Vincenzo Hospital, 98039 Taormina, Italy. giuseppe.mineo65@tiscali.it.
Maurizio MussoDivision of Hematology, La Maddalena Hospital, 90146 Palermo, Italy. mamusso@libero.it.
Ferdinando PorrettoDivision of Hematology, La Maddalena Hospital, 90146 Palermo, Italy. fporretto@alice.it.
Bruno MartinoHematology Department, Grande Ospedale Metropolitano, Reggio Calabria, 89124 Reggio Calabria, Italy. brunmartin@libero.it.
Francesco Di RaimondoDivision of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. diraimon@unict.it.
Livia ManzellaDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. manzella@unict.it.
Paolo VigneriDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. vigneripaolo@gmail.com.
Fabio StagnoDivision of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. fsematol@tiscali.it.ORCID 0000-0002-7947-158X
University of Catania · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITLa Maddalena · ITUniversity of Messina · ITAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITAzienda Usl 8 Arezzo · ITFondazione Vincenzo Pansadoro · ITOspedale Garibaldi · ITOspedale Vincenzo Cervello · ITUniversity of Reggio Calabria · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
A reduction in
Indexed as
AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorFemaleFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedProtein Kinase InhibitorsRNA, MessengerTreatment OutcomeAntineoplastic AgentsBCR-ABL1 fusion protein, humanBiomarkers, TumorFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsRNA, MessengerBCR-ABL1chronic myeloid leukemiaearly molecular responseEuropean Leukemia Netimatinib mesylate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.